Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes
Tope Olubodun, Morenike Adedoyin Osundina, David Olubukunmi Soyoye, Natalia Maria Bim de Oliveira, Ayodeji Bamidele Olubodun, Oluwatoyin Olanrewaju Ogundele · 2026
Read Gastroparesis induced by glucagon-like peptide-1 receptor agonists: A systematic review of clinical features, diagnosis, management, and outcomes by Tope Olubodun, Morenike Adedoyin Osundina, David Olubukunmi Soyoye, Natalia Maria Bim de Oliveira, Ayodeji Bamidele Olubodun, Oluwatoyin Olanrewaju Ogundele (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0354497.txt.
Description
Tope Olubodun and co-authors reviewed published cases of stomach paralysis linked to a popular class of diabetes and weight-loss drugs. These medicines, called GLP-1 receptor agonists, commonly slow the gut, but full gastroparesis is less recognised. Their 2026 systematic review searched four databases for real-world reports through late 2025.
Only twelve reports covering thirteen patients met the review's rules. Most patients were women with type 2 diabetes, though some had no diabetes. Semaglutide appeared most often, and symptoms began anywhere from hours to months after starting, often after a dose rise or careless restart. The authors urge clinicians to watch for the condition and to record cases carefully, since evidence remains thin.
Catalog record
| CREATOR | Tope Olubodun, Morenike Adedoyin Osundina, David Olubukunmi Soyoye, Natalia Maria Bim de Oliveira, Ayodeji Bamidele Olubodun, Oluwatoyin Olanrewaju Ogundele |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 67603 |
| LICENSE | CC_BY |
| RIGHTS | CC BY |
| SOURCE | PLOS |